This cohort study assesses whether baseline and early therapy circulating tumor DNA measurements differentiate pseudoprogression from true progression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies.
http://ift.tt/2nRT3D4
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου